The study compares the effects of combined treatment using sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) versus monotherapy on cancer-related hospitalization and mortality in general and cardiovascular disease (CVD) populations.
Results showed that patients receiving combined therapy had a significantly lower risk of cancer mortality compared to those on monotherapy, regardless of their CVD status.
The main factors associated with higher cancer mortality included being male and older age, with diabetes being present in 97% of the study population.
Atrial fibrosis impacts the success of ablation procedures, with extensive fibrosis potentially reducing atrial excitability.
The study aimed to determine clinical factors linked to extensive left atrial myopathy (ELAM) and evaluate the effectiveness of existing prediction scores for assessing outcomes related to atrial fibrillation (AF) recurrence.
Results showed that 8.4% of patients had ELAM, with predictors being age, female sex, persistent AF, and first-degree AV block, leading to higher rates of AF recurrence and heart failure admissions compared to non-ELAM patients.